CD19 and lymphoma: In preclinical models of human CAR-refractory lymphoma, STK-009 treatment resulted in systemic and intra-tumoral expansion and activation of hoRb-expressing anti–CD19-CD28ζ CAR-T cells (SYNCAR-001).